Business Wire

Understanding the Link Between NAFLD and Diabetes: Echosens Points to New AACE Guideline Supporting FibroScan as Key Component of Type 2 Diabetes Management

WALTHAM, Mass.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, recognizes the importance of American Diabetes Month this November ...
Business Wire

Echosens and ChronWell Announce Exclusive Strategic Partnership Between FibroScan and LIVErHEALTHY to Improve Patient Outcomes and Cost Savings

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...
Healio

Sex hormone-binding globulin level may predict liver fibrosis for men with NAFLD

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Higher sex hormone-binding globulin levels may predict liver fibrosis for men with nonalcoholic ...
Medscape

In Two Analyses, MAESTRO-NAFLD-1 Trial Shows Safety of Resmetirom

LONDON — Resmetirom (Madrigal Pharmaceuticals) is a safe option for patients with nonalcoholic steatohepatitis (NASH), according to a pair of studies sharing results from the phase 3 MAESTRO NAFLD-1 ...
Healio

Noninvasive testing for NAFLD crucial for people with diabetes

Please provide your email address to receive an email when new articles are posted on . Providers should closely monitor people with diabetes and other high-risk adults for nonalcoholic fatty liver ...
Nasdaq

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, ...